Quantcast

Study Shows Pine Bark Naturally Reduces Inflammatory Marker CRP in Osteoarthritis

December 9, 2008

Third osteoarthritis study this year reveals Pycnogenol(R) lowers inflammatory marker CRP

HOBOKEN, N.J., Dec. 9 /PRNewswire/ — Osteoarthritis (OA), a type of arthritis caused by the breakdown and loss of cartilage, affects more than 20 million Americans. While the most common prescription to treat OA is non-steroidal anti-inflammatory drugs (NSAIDs), many seek alternative treatments because of the side effects associated with these drugs. Pycnogenol(R) (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, has been shown to reduce osteoarthritis in multiple studies. A study published in the current issue of the journal Redox Report, reveals Pycnogenol’s(R) anti-inflammatory potency further to improving OA symptoms and pain was able to significantly lower plasma levels of C-reactive protein (CRP). With disease progression of osteoarthritis, the inflammation may reach a level where it no longer is limited to the affected joint and stresses the organisms, which in turn increases the inflammatory marker CRP in the blood.

The current study, a joint effort between Italy’s Chieti-Pescara University and the University of Munster, Germany, investigated a subset 55 patients from a previous osteoarthritis with 156 patients who had significantly elevated CRP levels. Treatment consisted of two tablets daily of either 50 mg Pycnogenol or placebo. Blood specimens were drawn at baseline of the initial study and again after three-month treatment. Results showed that Pycnogenol(R) significantly lowered CRP from average 3.9 mg/L at baseline to 1.1 mg/L, reflecting essentially healthy levels. In the placebo group a marginal lowered CRP level was detected. Other blood parameters indicative of acute inflammation likewise decreased with Pycnogenol, such as fibrinogen (lowered 37.1 %) and reactive oxygen species (lowered by 29.9 %).

“The decrease of systemic inflammatory markers, particularly CRP, suggests Pycnogenol(R) properties may be potent enough to arrest the spread of inflammation from osteoarthritic joints to the whole organisms,” said Dr. Peter Rohdewald, a lead researcher of the study. “When inflammatory processes are allowed to reach the whole body the degenerative processes may burden overall health including increased cardiovascular risks.”

About Pycnogenol(R)

Pycnogenol(R) is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol(R) is available in more than 600 dietary supplements, multi-vitamins and health products worldwide. For more information, visit www.pycnogenol.com.

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol(R) (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol(R) is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. NHS has the exclusive rights to market and sell Pycnogenol(R) in North America and benefits from more than 35 years of scientific research assuring the safety and efficacy of Pycnogenol(R) as a dietary supplement. For more information about Pycnogenol(R) visit our Web site at www.pycnogenol.com.

SOURCE Natural Health Science Inc.


Source: newswire



comments powered by Disqus